Max Medina-Ramírez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Max Medina-Ramírez has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anila Yasmeen
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA
1 shared publication - John P. Moore
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA
1 shared publication - Kwinten Sliepen
Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
1 shared publication - Per Johan Klasse
Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA
1 shared publication Quentin J. Sattentau
Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, UK
1 shared publicationRogier W. Sanders
Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 May 2017
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 12 (3) , 241-249
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
To provide an update on the latest developments in the field of HIV-1 antibody-based soluble envelope glycoprotein (Env) trimer design for vaccine use. The development of soluble native-like HIV-1 Env trimer immunogens has moved the field of antibody-based vaccine design forward dramatically over the past few years with refinement of various stabilizing approaches. However, despite this progress, significant challenges remain. Firstly, although trimers are relatively stable in solution, they nevertheless sample different conformational states, some of which may be less relevant to binding and induction of broadly neutralizing antibodies (bNAbs). Secondly, these trimers expose unwanted immunodominant surfaces that may distract the adaptive immune response from recognizing more immunorecessive but conserved neutralization-relevant surfaces on the trimer. The availability of atomic-resolution structural information has allowed guided design of mutations that have further stabilized trimers and allowed reduced exposure of unwanted epitopes. Moreover, chemical cross-linking approaches that do not require structural information have also contributed to trimer stabilization and selection of particular conformational forms. However, current knowledge suggests that strategies additional to trimer stabilization will be required to elicit bNAb, including targeting naïve B cell receptors with specific immunogens, and guiding B cell lineages toward recognizing conserved surfaces on Env with high affinity. This review will give a perspective on these challenges, and summarize current approaches to overcoming them with the aim of developing immunogens to elicit bNAb responses in humans by active vaccination.
- 1 May 2017
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 12 (3) , 241-249
Open AccessStabilized HIV-1 envelope glycoprotein trimers for vaccine use
To provide an update on the latest developments in the field of HIV-1 antibody-based soluble envelope glycoprotein (Env) trimer design for vaccine use. The development of soluble native-like HIV-1 Env trimer immunogens has moved the field of antibody-based vaccine design forward dramatically over the past few years with refinement of various stabilizing approaches. However, despite this progress, significant challenges remain. Firstly, although trimers are relatively stable in solution, they nevertheless sample different conformational states, some of which may be less relevant to binding and induction of broadly neutralizing antibodies (bNAbs). Secondly, these trimers expose unwanted immunodominant surfaces that may distract the adaptive immune response from recognizing more immunorecessive but conserved neutralization-relevant surfaces on the trimer. The availability of atomic-resolution structural information has allowed guided design of mutations that have further stabilized trimers and allowed reduced exposure of unwanted epitopes. Moreover, chemical cross-linking approaches that do not require structural information have also contributed to trimer stabilization and selection of particular conformational forms. However, current knowledge suggests that strategies additional to trimer stabilization will be required to elicit bNAb, including targeting naïve B cell receptors with specific immunogens, and guiding B cell lineages toward recognizing conserved surfaces on Env with high affinity. This review will give a perspective on these challenges, and summarize current approaches to overcoming them with the aim of developing immunogens to elicit bNAb responses in humans by active vaccination.